You actually can't compare doses between completely different drugs - e.g. to treat HBV you would use 0.5mg of entecavir or 300mg of tenofovir to achieve the same effect. Hopefully for Biotron reducing the dose of BIT225 might reduce toxicity (which will almost certainly be the cause of the withdrawals) without losing efficacy. What the results suggest (as much as we are party to), however, is that the margin between tolerating the drug and not tolerating it is small, and given that it is likely there's at least a twofold difference in drug metabolism across the population, it will make producing a fixed dose combination tablet extremely difficult, making BIT225 less attractive to potential partners. The less attractive, the more likely shareholders will be funding ongoing drug development themselves through future capital raisings.
BIT Price at posting:
11.0¢ Sentiment: Sell Disclosure: Not Held
